GRANT COLLABORATON AGREEMENT (Details Narrative) - Cystic Fibrosis Foundation [Member] - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |
---|---|---|---|
Feb. 10, 2021 |
Sep. 30, 2022 |
Sep. 30, 2022 |
|
Product Information [Line Items] | |||
Grants Receivable | $ 2,170 | ||
Reduction of research and development expense | $ 1,510 | ||
Other Expenses | $ 181 | $ 338 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | |||
Product Information [Line Items] | |||
Concentration Risk, Percentage | 10.00% |
X | ||||||||||
- Definition Reduction of research and development expenses. No definition available.
|
X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|